Remission

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled hypericum arms (n=147), early improvement in somatic-gastrointestinal (p<0.001, r2=0.262) and hypochondriasis (p=0.004, r2=0.218) items from baseline to week 1 significantly predicted re

Effect: improvement; somatic-GI: p<0.001, r2=0.262; hypochondriasis: p=0.004, r2=0.218

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184